Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Ipilimumab in Melanoma, Cutaneous Malignant: NCT07740941 Clinical Landscape Report 2026
11 September 2026
NCT07740941 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HRS-4729 in Metabolic Dysfunction Associated Steatohepatitis: NCT07660848 Clinical Landscape Report 2026
11 September 2026
NCT07660848 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Iparomlimab/Tuvonralimab in Mesothelioma: NCT07514793 Clinical Landscape Report 2026
11 September 2026
NCT07514793 clinical landscape for Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PBSS-1113 in Acute Myeloid Leukemia: NCT07761533 Clinical Landscape Report 2026
11 September 2026
NCT07761533 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Glofitamab in Mantle cell lymphoma refractory: NCT07748364 Clinical Landscape Report 2026
11 September 2026
NCT07748364 clinical landscape for Mantle cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Oxaliplatin in Locally Advanced Rectal Carcinoma: NCT07811076 Clinical Landscape Report 2026
11 September 2026
NCT07811076 clinical landscape for Locally Advanced Rectal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
MWN-109 in Diabetes Mellitus, Type 2: NCT07801326 Clinical Landscape Report 2026
11 September 2026
NCT07801326 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Triple Negative Breast Cancer: NCT07768436 Clinical Landscape Report 2026
11 September 2026
NCT07768436 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AUTO-4(University College London) in Sarcoma: NCT07751380 Clinical Landscape Report 2026
11 September 2026
NCT07751380 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sacituzumab tirumotecan in Non-Muscle Invasive Bladder Urothelial Carcinoma: NCT07716917 Clinical Landscape Report 2026
11 September 2026
NCT07716917 clinical landscape for Non-Muscle Invasive Bladder Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Tezepelumab in Severe asthma: NCT07013123 Clinical Landscape Report 2026
11 September 2026
NCT07013123 clinical landscape for Severe asthma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HS-20118 in Plaque psoriasis: NCT07765628 Clinical Landscape Report 2026
11 September 2026
NCT07765628 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.